Analyst ratings shift for major companies like Disney and HP, while HPE reports impressive revenue growth despite cash flow concerns. Plus, updates on Installed Building Products, MeridianLink, and Sunrun. Read more...

A roundup of recent analyst ratings and price target adjustments for companies like NetApp, Lexicon Pharmaceuticals, Medpace Holdings, and more. Plus, a look at Nvidia vs. Broadcom in the AI space. Read more...

Recent analyst downgrades have impacted the stock prices of several companies listed on the NYSE, including AES, Dell Technologies, GE Vernova, and Cava Group. This article provides an overview of these changes and their potential implications. Read more...

Several stocks have seen recent target price adjustments by analysts. This article summarizes the latest ratings and price target changes for Owens Corning, AES, ON, Fulgent Genetics, and Rexford Industrial Realty. Read more...

Scotiabank's recent analyst actions have significantly impacted several companies, with upgrades and downgrades affecting stock prices for firms like AT&T, Janux Therapeutics, and others. Read more...

Recent stock market activity includes changes in holdings for Wingstop, increased short interest in Alto Ingredients and Amalgamated Financial, and analyst upgrades for Okta and Roivant Sciences. Read more...

Citigroup mistakenly credited a client with $81 trillion, while China aims for 5% economic growth despite trade tensions with the US. This article examines both stories. Read more...

Recent analyst reports show mixed outlooks for Kimbell Royalty Partners, Sempra, Myriad Genetics, and Okta, with revised price targets and ratings. Read more...

Bullion banks are increasing their gold and silver price targets as gold hits record highs. Plus, concerns rise over a shortage of deliverable gold and a child racks up a huge app store bill. Read more...

Recent analyst reports have adjusted price targets for several stocks, including Fortrea, Docebo, and Silence Therapeutics. We examine these changes and their potential impact. Read more...

Citigroup faces scrutiny after an $81 trillion error and fluctuating analyst ratings for stocks like Abbott Labs, Bio-Techne, Thermo Fisher, Mettler-Toledo, and Okta. Read more...

Raymond James adjusts its price target for Viant Technology and revises earnings estimates for Elemental Altus Royalties, impacting investor outlook. Read more...

Recent analyst reports have adjusted price targets and ratings for several companies, including Talen Energy, Sunnova Energy, GitLab, Kohl's, and ThredUp. Read more...

Stifel Nicolaus has recently initiated coverage on several companies, including Martin Marietta Materials, Sionna Therapeutics, and Vulcan Materials, issuing "buy" ratings and setting price targets. Lightspeed Commerce Inc. receives a "Moderate Buy" consensus. Read more...

A roundup of recent analyst ratings for various stocks, including Astronics, Lloyds Banking Group, Oklo, Amylyx Pharmaceuticals, NatWest Group, and GE Vernova, providing insights for investors. Read more...

Citigroup has been actively adjusting price targets and initiating coverage across various sectors, impacting companies like Bio-Techne, Hologic, and Titan America. Here's a quick rundown. Read more...

Several companies have seen their price targets adjusted by analysts recently. Barclays, Morgan Stanley, Guggenheim, and Wells Fargo have updated their outlooks on various stocks. Read more...

Recent analyst reports show positive momentum for YETI, ON Semiconductor, and Eli Lilly, with raised price targets and continued "overweight" ratings. Plus, a look at Caterpillar as a potential dividend stock. Read more...

Okta (OKTA) receives multiple analyst upgrades and price target increases from firms like KeyCorp, DA Davidson, Mizuho, and Goldman Sachs, signaling strong market confidence. Read more...

Cantor Fitzgerald has issued "strong-buy" ratings for multiple stocks, including Immunovant, Ardelyx, Kura Oncology, and Mesoblast. Meanwhile, Bank of America adjusts price targets for Gilead Sciences and Immunovant. Read more...